CliffBio
biologic

OTARMENI

lunsotogene parvec-cwha

Loss of exclusivity—loss of exclusivity
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameOTARMENI
Active ingredientlunsotogene parvec-cwha
Strength3x10^13VG/ML
Dosage formSuspension
RouteIntracochlear
ModalityBiologic
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OTARMENI patent cliff — loss of exclusivity — | CliffBio